Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 1, 2002

View Archived Issues

Highly effective antinephritic agent derived from linomide

Large study compares cannabinoid and progesterone in cancer-associated anorexia

Optimal glycemic control obtained on mealtime repaglinide

Neuroprotective effects of an MLK-targeting indolocarbazole analogue

Available data on AWD-12-281, a new respiratory therapeutic, summarized

Abgenix reports on Q4 and year-end 2001 product development

BioCryst announces fourth-quarter results

Icos summarizes 2001 highlights

CVT-2759 more selective than adenosine in attenuating catecholamine-induced arrhythmia

Progress reported by North American Scientific on molecular imaging agent

Alesse approved by Canadian authorities for treatment of acne

Chugai cleared to resume clinical trials of GM-611

InterMune relaunches Infergen for hepatitis C infections

Phase IIb trial of ATL-1251 in mixed-symptom IBS cleared by U.K. authorities

Amersham Health and Pfizer collaborate to link early disease diagnosis and treatment

J&J selects validated drug targets from oncology collaboration with Rigel

Agouron terminates HIV target collaboration with PPD Discovery

Aromatic carboxamides effective as orexin-1 receptor antagonists

Schering-Plough discloses use and preparation of thrombin and CB2 receptor antagonists

Novel heterocyclic compounds with potential utility in neuropathies, etc.

Integrin receptor inhibitors identified at Merck KGaA

Boehringer Ingelheim prepares non-nucleoside compounds that inhibit HIV reverse transcriptase

Researchers at Senju claim chymase inhibitors for cardiovascular disease Rx

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 22, 2025.
In 2025, science’s biggest story was political
BioWorld
In 2025, science saw its breakthroughs, which BioWorld will be covering as part of our end-of-the-year wrap-up. But the biggest science story of 2025 is not about...
FDA says yes to Cytokinetics’ aficamten, now Myqorzo, in oHCM
BioWorld
Cytokinetics Inc. scored U.S. FDA marketing clearance Dec. 19 for Myqorzo (aficamten) 5-mg, 10-mg, 15-mg, and 20-mg tablets to improve functional capacity and...
Conjugating ferrocene to GPX4 inhibitors to promote ferroptosis
BioWorld Science
Small molecules that induce iron-dependent oxidative cell death known as ferroptosis can be effective against tumors that are resistant to other therapies....